News coverage about TRACON Pharmaceuticals (NASDAQ:TCON) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.1819317341445 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, Zacks Investment Research upgraded shares of TRACON Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a report on Saturday, November 11th.
TRACON Pharmaceuticals (TCON) traded down $0.30 during midday trading on Friday, reaching $2.90. 245,200 shares of the company traded hands, compared to its average volume of 152,519. TRACON Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $5.70. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.80 and a quick ratio of 3.80. The stock has a market capitalization of $50.78, a price-to-earnings ratio of -2.38 and a beta of 2.41.
TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.32. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 83.43%. The firm had revenue of $7.50 million for the quarter, compared to analyst estimates of $7.60 million. sell-side analysts anticipate that TRACON Pharmaceuticals will post -1.21 earnings per share for the current fiscal year.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/14/tracon-pharmaceuticals-tcon-earning-somewhat-positive-press-coverage-report-shows.html.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.